

Supplementary Materials for
Consolidated Financial Results for
Fiscal Year 2018. 12 (IFRS)

Innovation all for the patients



CHUGAI PHARMACEUTICAL CO., LTD.



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts
3. Exchange rates used for each period are as follows.

QTR

(Yen)

		Actual*				Actual*			
		FY2017				FY2018			
		1-3	4-6	7-9	10-12	1-3	4-6	7-9	10-12
		QTR	QTR	QTR	QTR	QTR	QTR	QTR	QTR
CHF		113.21	112.69	115.33	114.41	114.33	110.77	113.32	113.33
EUR		121.09	122.03	130.36	132.93	133.17	130.06	129.66	128.72
USD		113.69	111.07	111.01	112.89	108.40	109.08	111.47	112.84
SGD		80.25	79.76	81.57	83.38	82.16	81.78	81.51	82.04

*Market average exchange rate

YTD

	Actual*	Actual*				Actual*				Assumption
		FY2017				FY2018				FY2019
		1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12
		Full-year	YTD	YTD	YTD	Full-year	YTD	YTD	YTD	Full-year
CHF	110.46	113.21	112.95	113.73	113.90	114.33	112.52	112.79	112.92	114.00
EUR	120.42	121.09	121.55	124.33	126.39	133.17	131.59	130.93	130.36	128.00
USD	108.83	113.69	112.38	111.92	112.17	108.40	108.74	109.65	110.45	111.00
SGD	78.82	80.25	80.01	80.52	81.22	82.16	81.97	81.81	81.87	82.00

*Market average exchange rate

Period-end

	Actual	Actual				Actual			
		FY2017				FY2018			
		31 Dec.	31 Mar.	30 Jun.	30 Sep.	31 Dec.	31 Mar.	30 Jun.	30 Sep.
CHF	113.94	111.76	117.37	115.80	115.35	111.67	110.78	116.01	112.03
EUR	122.27	119.47	128.35	132.41	134.82	131.49	127.83	131.98	126.13
USD	116.55	111.92	112.18	112.35	112.89	106.83	110.50	113.38	110.28
SGD	80.47	80.04	81.33	82.73	84.39	81.43	80.79	82.88	80.70

Reconciliation of IFRS results to Core results

(Billions of yen)

	FY2017				FY2018			
	1-12				1-12			
	IFRS results	Intangible assets	Others	Core results	IFRS results	Intangible assets	Others	Core results
Revenues	534.2	–	–	534.2	579.8	–	–	579.8
Sales	499.3	–	–	499.3	527.8	–	–	527.8
Royalties and other operating income	34.9	–	–	34.9	51.9	–	–	51.9
Cost of sales	(254.2)	1.2	–	(252.9)	(262.8)	1.0	–	(261.9)
Gross profit	280.0	1.2	–	281.3	316.9	1.0	–	317.9
Operating expenses	(181.1)	4.0	(1.0)	(178.1)	(192.6)	5.0	–	(187.6)
Marketing and distribution	(72.8)	–	–	(72.8)	(73.7)	–	–	(73.7)
Research and development	(92.9)	4.0	–	(88.9)	(99.2)	5.0	–	(94.2)
General and administration	(15.3)	–	(1.0)	(16.3)	(19.7)	–	–	(19.7)
Operating profit	98.9	5.3	(1.0)	103.2	124.3	6.0	–	130.3
Financing costs	(0.1)	–	–	(0.1)	(0.1)	–	–	(0.1)
Other financial income (expense)	(0.1)	–	–	(0.1)	0.4	–	–	0.4
Other expense	(1.7)	–	–	(1.7)	(3.2)	–	–	(3.2)
Profit before taxes	97.0	5.3	(1.0)	101.3	121.4	6.0	–	127.5
Income taxes	(23.5)	(1.4)	0.3	(24.5)	(28.4)	(1.8)	–	(30.2)
Net income	73.5	3.9	(0.7)	76.7	93.1	4.2	–	97.3
Attributable to								
Chugai shareholders	72.7	3.9	(0.7)	75.9	92.5	4.2	–	96.7
Non-controlling interests	0.8	–	–	0.8	0.6	–	–	0.6

Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its decision to apply IFRS. Core results are the results after adjusting non-Core items to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the underlying business performance both internally and externally, and as the basis for payment-by-results such as a return to shareholders.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

Intangible assets

Amortization (1.3 billion yen in 2017 and 1.2 billion yen in 2018)

Impairment (4.0 billion yen in 2017 and 4.8 billion yen in 2018)

Others

Legal income and expenses (–1.0 billion yen in 2017 and none in 2018)

IFRS results (QTR)

(Billions of yen)

	Actual				Actual							
	FY2017				FY2018							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenues	125.5	127.3	134.9	146.6	147.4	+17.5	137.7	+8.2	141.3	+4.7	153.3	+4.6
Sales	118.1	118.7	127.9	134.5	124.7	+5.6	130.8	+10.2	133.1	+4.1	139.1	+3.4
excl. Tamiflu	110.8	117.9	126.1	127.7	116.3	+5.0	130.8	+10.9	132.7	+5.2	137.3	+7.5
Domestic	85.1	97.9	97.9	107.5	84.5	(0.7)	98.3	+0.4	99.2	+1.3	107.3	(0.2)
Sales to Roche	21.3	15.6	23.7	15.8	27.4	+28.6	27.8	+78.2	28.9	+21.9	25.8	+63.3
Overseas	4.3	4.5	4.4	4.5	4.5	+4.7	4.7	+4.4	4.5	+2.3	4.3	(4.4)
Tamiflu sales	7.4	0.8	1.9	6.8	8.4	+13.5	0.0	(100.0)	0.4	(78.9)	1.8	(73.5)
Ordinary use	6.1	0.2	0.0	5.6	8.3	+36.1	0.0	(100.0)	0.0	0.0	1.8	(67.9)
Govt. stockpiles etc.	1.3	0.6	1.8	1.2	0.1	(92.3)	–	(100.0)	0.4	(77.8)	–	(100.0)
Royalties and other operating income	7.3	8.6	6.9	12.0	22.7	+211.0	6.8	(20.9)	8.2	+18.8	14.2	+18.3
Cost of sales	(61.2)	(60.3)	(65.1)	(67.7)	(63.8)	+4.2	(65.2)	+8.1	(65.9)	+1.2	(67.8)	+0.1
(% of Sales)	51.8	50.8	50.9	50.3	51.2	–	49.8	–	49.5	–	48.7	–
Gross profit	64.3	67.0	69.8	78.9	83.6	+30.0	72.5	+8.2	75.4	+8.0	85.5	+8.4
(% of Revenues)	51.2	52.6	51.7	53.8	56.7	–	52.7	–	53.4	–	55.8	–
Operating expenses	(38.0)	(46.3)	(40.7)	(56.2)	(45.2)	+18.9	(44.2)	(4.5)	(44.0)	+8.1	(59.1)	+5.2
(% of Revenues)	30.3	36.4	30.2	38.3	30.7	–	32.1	–	31.1	–	38.6	–
Marketing and distribution	(15.4)	(16.8)	(17.0)	(23.6)	(15.9)	+3.2	(17.3)	+3.0	(17.2)	+1.2	(23.3)	(1.3)
(% of Revenues)	12.3	13.2	12.6	16.1	10.8	–	12.6	–	12.2	–	15.2	–
Research and development	(19.3)	(25.6)	(20.8)	(27.3)	(25.1)	+30.1	(23.5)	(8.2)	(22.3)	+7.2	(28.3)	+3.7
(% of Revenues)	15.4	20.1	15.4	18.6	17.0	–	17.1	–	15.8	–	18.5	–
General and administration	(3.3)	(3.9)	(2.9)	(5.3)	(4.3)	+30.3	(3.5)	(10.3)	(4.4)	+51.7	(7.5)	+41.5
(% of Revenues)	2.6	3.1	2.1	3.6	2.9	–	2.5	–	3.1	–	4.9	–
Operating profit	26.3	20.8	29.1	22.7	38.4	+46.0	28.2	+35.6	31.3	+7.6	26.4	+16.3
(% of Revenues)	21.0	16.3	21.6	15.5	26.1	–	20.5	–	22.2	–	17.2	–
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0
Other financial income (expense)	(0.3)	0.1	0.0	0.1	(0.1)	(66.7)	0.1	0.0	(0.1)	–	0.5	+400.0
Other expense	(1.1)	0.7	(0.7)	(0.6)	(0.6)	(45.5)	(0.9)	–	(0.6)	(14.3)	(1.1)	+83.3
Profit before taxes	25.0	21.5	28.4	22.2	37.7	+50.8	27.3	+27.0	30.6	+7.7	25.8	+16.2
(% of Revenues)	19.9	16.9	21.1	15.1	25.6	–	19.8	–	21.7	–	16.8	–
Income taxes	(6.2)	(3.6)	(7.1)	(6.5)	(9.5)	+53.2	(6.4)	+77.8	(8.8)	+23.9	(3.6)	(44.6)
Net income	18.7	17.8	21.3	15.7	28.2	+50.8	20.9	+17.4	21.8	+2.3	22.2	+41.4
(% of Revenues)	14.9	14.0	15.8	10.7	19.1	–	15.2	–	15.4	–	14.5	–
Attributable to												
Chugai shareholders	18.5	17.6	21.1	15.5	27.9	+50.8	20.8	+18.2	21.7	+2.8	22.1	+42.6
Non-controlling interests	0.2	0.2	0.2	0.2	0.3	+50.0	0.1	(50.0)	0.2	0.0	0.1	(50.0)
Earnings per share												
Basic (yen)	33.86	32.20	38.59	28.38	51.00	+50.6	38.00	+18.0	39.60	+2.6	40.48	+42.6
Diluted (yen)	33.81	32.15	38.53	28.33	50.91	+50.6	37.94	+18.0	39.54	+2.6	40.41	+42.6

Other financial income (expense) includes net amount of FX related gains/losses.

IFRS results (YTD)

(Billions of yen)

	Actual	Actual				Actual							
	FY2016	FY2017				FY2018							
	1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)
	YTD	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD	
Revenues	491.8	125.5	252.8	387.6	534.2	147.4	+17.5	285.1	+12.8	426.4	+10.0	579.8	+8.5
Sales	472.7	118.1	236.8	364.8	499.3	124.7	+5.6	255.6	+7.9	388.7	+6.6	527.8	+5.7
excl. Tamiflu	459.2	110.8	228.7	354.8	482.4	116.3	+5.0	247.2	+8.1	379.8	+7.0	517.2	+7.2
Domestic	379.7	85.1	183.0	281.0	388.4	84.5	(0.7)	182.7	(0.2)	281.9	+0.3	389.2	+0.2
Sales to Roche	62.8	21.3	36.9	60.6	76.4	27.4	+28.6	55.2	+49.6	84.2	+38.9	109.9	+43.8
Overseas	16.8	4.3	8.8	13.2	17.7	4.5	+4.7	9.2	+4.5	13.7	+3.8	18.0	+1.7
Tamiflu sales	13.5	7.4	8.2	10.0	16.9	8.4	+13.5	8.4	+2.4	8.9	(11.0)	10.7	(36.7)
Ordinary use	12.0	6.1	6.3	6.3	11.9	8.3	+36.1	8.3	+31.7	8.3	+31.7	10.1	(15.1)
Govt. stockpiles etc.	1.5	1.3	1.9	3.7	5.0	0.1	(92.3)	0.1	(94.7)	0.5	(86.5)	0.5	(90.0)
Royalties and other operating income	19.1	7.3	15.9	22.9	34.9	22.7	+211.0	29.5	+85.5	37.7	+64.6	51.9	+48.7
Cost of sales	(247.9)	(61.2)	(121.4)	(186.5)	(254.2)	(63.8)	+4.2	(129.1)	+6.3	(195.0)	+4.6	(262.8)	+3.4
(% of Sales)	52.4	51.8	51.3	51.1	50.9	51.2	–	50.5	–	50.2	–	49.8	–
Gross profit	243.8	64.3	131.3	201.1	280.0	83.6	+30.0	156.1	+18.9	231.4	+15.1	316.9	+13.2
(% of Revenues)	49.6	51.2	51.9	51.9	52.4	56.7	–	54.8	–	54.3	–	54.7	–
Operating expenses	(167.0)	(38.0)	(84.2)	(124.9)	(181.1)	(45.2)	+18.9	(89.5)	+6.3	(133.5)	+6.9	(192.6)	+6.4
(% of Revenues)	34.0	30.3	33.3	32.2	33.9	30.7	–	31.4	–	31.3	–	33.2	–
Marketing and distribution	(69.8)	(15.4)	(32.2)	(49.2)	(72.8)	(15.9)	+3.2	(33.2)	+3.1	(50.4)	+2.4	(73.7)	+1.2
(% of Revenues)	14.2	12.3	12.7	12.7	13.6	10.8	–	11.6	–	11.8	–	12.7	–
Research and development	(85.0)	(19.3)	(44.8)	(65.7)	(92.9)	(25.1)	+30.1	(48.5)	+8.3	(70.9)	+7.9	(99.2)	+6.8
(% of Revenues)	17.3	15.4	17.7	17.0	17.4	17.0	–	17.0	–	16.6	–	17.1	–
General and administration	(12.2)	(3.3)	(7.2)	(10.0)	(15.3)	(4.3)	+30.3	(7.8)	+8.3	(12.2)	+22.0	(19.7)	+28.8
(% of Revenues)	2.5	2.6	2.8	2.6	2.9	2.9	–	2.7	–	2.9	–	3.4	–
Operating profit	76.9	26.3	47.1	76.2	98.9	38.4	+46.0	66.6	+41.4	97.9	+28.5	124.3	+25.7
(% of Revenues)	15.6	21.0	18.6	19.7	18.5	26.1	–	23.4	–	23.0	–	21.4	–
Financing costs	(0.1)	(0.0)	(0.1)	(0.1)	(0.1)	(0.0)	0.0	(0.1)	0.0	(0.1)	0.0	(0.1)	0.0
Other financial income (expense)	1.1	(0.3)	(0.2)	(0.2)	(0.1)	(0.1)	(66.7)	0.0	–	(0.1)	(50.0)	0.4	–
Other expense	(3.5)	(1.1)	(0.4)	(1.1)	(1.7)	(0.6)	(45.5)	(1.5)	+275.0	(2.1)	+90.9	(3.2)	+88.2
Profit before taxes	74.4	25.0	46.4	74.9	97.0	37.7	+50.8	65.0	+40.1	95.6	+27.6	121.4	+25.2
(% of Revenues)	15.1	19.9	18.4	19.3	18.2	25.6	–	22.8	–	22.4	–	20.9	–
Income taxes	(20.1)	(6.2)	(9.9)	(17.0)	(23.5)	(9.5)	+53.2	(15.9)	+60.6	(24.8)	+45.9	(28.4)	+20.9
Net income	54.4	18.7	36.5	57.9	73.5	28.2	+50.8	49.0	+34.2	70.9	+22.5	93.1	+26.7
(% of Revenues)	11.1	14.9	14.4	14.9	13.8	19.1	–	17.2	–	16.6	–	16.1	–
Attributable to													
Chugai shareholders	53.6	18.5	36.1	57.2	72.7	27.9	+50.8	48.7	+34.9	70.3	+22.9	92.5	+27.2
Non-controlling interests	0.8	0.2	0.4	0.7	0.8	0.3	+50.0	0.4	0.0	0.5	(28.6)	0.6	(25.0)
Earnings per share													
Basic (yen)	98.12	33.86	66.07	104.66	133.04	51.00	+50.6	89.00	+34.7	128.60	+22.9	169.08	+27.1
Diluted (yen)	97.97	33.81	65.97	104.51	132.83	50.91	+50.6	88.85	+34.7	128.39	+22.8	168.80	+27.1

Other financial income (expense) includes net amount of FX related gains/losses.

Core results (QTR)

(Billions of yen)

	Actual				Actual							
	FY2017				FY2018							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Revenues	125.5	127.3	134.9	146.6	147.4	+17.5	137.7	+8.2	141.3	+4.7	153.3	+4.6
Sales	118.1	118.7	127.9	134.5	124.7	+5.6	130.8	+10.2	133.1	+4.1	139.1	+3.4
excl. Tamiflu	110.8	117.9	126.1	127.7	116.3	+5.0	130.8	+10.9	132.7	+5.2	137.3	+7.5
Domestic	85.1	97.9	97.9	107.5	84.5	(0.7)	98.3	+0.4	99.2	+1.3	107.3	(0.2)
Sales to Roche	21.3	15.6	23.7	15.8	27.4	+28.6	27.8	+78.2	28.9	+21.9	25.8	+63.3
Overseas	4.3	4.5	4.4	4.5	4.5	+4.7	4.7	+4.4	4.5	+2.3	4.3	(4.4)
Tamiflu sales	7.4	0.8	1.9	6.8	8.4	+13.5	0.0	(100.0)	0.4	(78.9)	1.8	(73.5)
Ordinary use	6.1	0.2	0.0	5.6	8.3	+36.1	0.0	(100.0)	0.0	0.0	1.8	(67.9)
Govt. stockpiles etc.	1.3	0.6	1.8	1.2	0.1	(92.3)	–	(100.0)	0.4	(77.8)	–	(100.0)
Royalties and other operating income	7.3	8.6	6.9	12.0	22.7	+211.0	6.8	(20.9)	8.2	+18.8	14.2	+18.3
Cost of sales	(60.9)	(60.0)	(64.8)	(67.3)	(63.5)	+4.3	(65.1)	+8.5	(65.7)	+1.4	(67.6)	+0.4
(% of Sales)	51.6	50.5	50.7	50.0	50.9	–	49.8	–	49.4	–	48.6	–
Gross profit	64.6	67.3	70.1	79.2	83.9	+29.9	72.6	+7.9	75.6	+7.8	85.8	+8.3
(% of Revenues)	51.5	52.9	52.0	54.0	56.9	–	52.7	–	53.5	–	56.0	–
Operating expenses	(37.9)	(43.8)	(41.7)	(54.7)	(41.1)	+8.4	(43.8)	0.0	(44.0)	+5.5	(58.7)	+7.3
(% of Revenues)	30.2	34.4	30.9	37.3	27.9	–	31.8	–	31.1	–	38.3	–
Marketing and distribution	(15.4)	(16.8)	(17.0)	(23.6)	(15.9)	+3.2	(17.3)	+3.0	(17.2)	+1.2	(23.3)	(1.3)
(% of Revenues)	12.3	13.2	12.6	16.1	10.8	–	12.6	–	12.2	–	15.2	–
Research and development	(19.2)	(23.1)	(20.8)	(25.8)	(20.9)	+8.9	(23.0)	(0.4)	(22.3)	+7.2	(27.9)	+8.1
(% of Revenues)	15.3	18.1	15.4	17.6	14.2	–	16.7	–	15.8	–	18.2	–
General and administration	(3.3)	(3.9)	(3.9)	(5.3)	(4.3)	+30.3	(3.5)	(10.3)	(4.4)	+12.8	(7.5)	+41.5
(% of Revenues)	2.6	3.1	2.9	3.6	2.9	–	2.5	–	3.1	–	4.9	–
Operating profit	26.7	23.5	28.5	24.5	42.8	+60.3	28.8	+22.6	31.6	+10.9	27.1	+10.6
(% of Revenues)	21.3	18.5	21.1	16.7	29.0	–	20.9	–	22.4	–	17.7	–
Financing costs	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0	(0.0)	0.0
Other financial income (expense)	(0.3)	0.1	0.0	0.1	(0.1)	(66.7)	0.1	0.0	(0.1)	–	0.5	+400.0
Other expense	(1.1)	0.7	(0.7)	(0.6)	(0.6)	(45.5)	(0.9)	–	(0.6)	(14.3)	(1.1)	+83.3
Profit before taxes	25.3	24.2	27.8	24.0	42.1	+66.4	28.0	+15.7	30.9	+11.2	26.5	+10.4
(% of Revenues)	20.2	19.0	20.6	16.4	28.6	–	20.3	–	21.9	–	17.3	–
Income taxes	(6.3)	(4.4)	(6.9)	(6.9)	(10.9)	+73.0	(6.6)	+50.0	(8.9)	+29.0	(3.8)	(44.9)
Net income	18.9	19.9	20.9	17.1	31.2	+65.1	21.3	+7.0	22.0	+5.3	22.7	+32.7
(% of Revenues)	15.1	15.6	15.5	11.7	21.2	–	15.5	–	15.6	–	14.8	–
Attributable to												
Chugai shareholders	18.7	19.6	20.6	16.9	31.0	+65.8	21.2	+8.2	21.8	+5.8	22.6	+33.7
Non-controlling interests	0.2	0.2	0.2	0.2	0.3	+50.0	0.1	(50.0)	0.2	0.0	0.1	(50.0)
Core earnings per share (diluted) (yen)	34.22	35.89	37.70	30.88	56.52	+65.2	38.75	+8.0	39.87	+5.8	41.28	+33.7

Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

Core results (YTD)

(Billions of yen)

		Actual	Actual				Actual							
		FY2016	FY2017				FY2018							
		1-12	1-3	1-6	1-9	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)
		YTD	YTD	YTD	YTD	YTD	YTD		YTD		YTD		YTD	
Revenues		491.8	125.5	252.8	387.6	534.2	147.4	+17.5	285.1	+12.8	426.4	+10.0	579.8	+8.5
Sales		472.7	118.1	236.8	364.8	499.3	124.7	+5.6	255.6	+7.9	388.7	+6.6	527.8	+5.7
excl. Tamiflu		459.2	110.8	228.7	354.8	482.4	116.3	+5.0	247.2	+8.1	379.8	+7.0	517.2	+7.2
Domestic		379.7	85.1	183.0	281.0	388.4	84.5	(0.7)	182.7	(0.2)	281.9	+0.3	389.2	+0.2
Sales to Roche		62.8	21.3	36.9	60.6	76.4	27.4	+28.6	55.2	+49.6	84.2	+38.9	109.9	+43.8
Overseas		16.8	4.3	8.8	13.2	17.7	4.5	+4.7	9.2	+4.5	13.7	+3.8	18.0	+1.7
Tamiflu sales		13.5	7.4	8.2	10.0	16.9	8.4	+13.5	8.4	+2.4	8.9	(11.0)	10.7	(36.7)
Ordinary use		12.0	6.1	6.3	6.3	11.9	8.3	+36.1	8.3	+31.7	8.3	+31.7	10.1	(15.1)
Govt. stockpiles etc.		1.5	1.3	1.9	3.7	5.0	0.1	(92.3)	0.1	(94.7)	0.5	(86.5)	0.5	(90.0)
Royalties and other operating income		19.1	7.3	15.9	22.9	34.9	22.7	+211.0	29.5	+85.5	37.7	+64.6	51.9	+48.7
Cost of sales		(246.7)	(60.9)	(120.8)	(185.6)	(252.9)	(63.5)	+4.3	(128.6)	+6.5	(194.3)	+4.7	(261.9)	+3.6
(% of Sales)		52.2	51.6	51.0	50.9	50.7	50.9	—	50.3	—	50.0	—	49.6	—
Gross profit		245.0	64.6	131.9	202.1	281.3	83.9	+29.9	156.6	+18.7	232.1	+14.8	317.9	+13.0
(% of Revenues)		49.8	51.5	52.2	52.1	52.7	56.9	—	54.9	—	54.4	—	54.8	—
Operating expenses		(164.5)	(37.9)	(81.8)	(123.4)	(178.1)	(41.1)	+8.4	(84.9)	+3.8	(128.9)	+4.5	(187.6)	+5.3
(% of Revenues)		33.4	30.2	32.4	31.8	33.3	27.9	—	29.8	—	30.2	—	32.4	—
Marketing and distribution		(69.8)	(15.4)	(32.2)	(49.2)	(72.8)	(15.9)	+3.2	(33.2)	+3.1	(50.4)	+2.4	(73.7)	+1.2
(% of Revenues)		14.2	12.3	12.7	12.7	13.6	10.8	—	11.6	—	11.8	—	12.7	—
Research and development		(82.6)	(19.2)	(42.4)	(63.2)	(88.9)	(20.9)	+8.9	(44.0)	+3.8	(66.3)	+4.9	(94.2)	+6.0
(% of Revenues)		16.8	15.3	16.8	16.3	16.6	14.2	—	15.4	—	15.5	—	16.2	—
General and administration		(12.1)	(3.3)	(7.2)	(11.0)	(16.3)	(4.3)	+30.3	(7.8)	+8.3	(12.2)	+10.9	(19.7)	+20.9
(% of Revenues)		2.5	2.6	2.8	2.8	3.1	2.9	—	2.7	—	2.9	—	3.4	—
Operating profit		80.6	26.7	50.2	78.7	103.2	42.8	+60.3	71.6	+42.6	103.3	+31.3	130.3	+26.3
(% of Revenues)		16.4	21.3	19.9	20.3	19.3	29.0	—	25.1	—	24.2	—	22.5	—
Financing costs		(0.1)	(0.0)	(0.1)	(0.1)	(0.1)	(0.0)	0.0	(0.1)	0.0	(0.1)	0.0	(0.1)	0.0
Other financial income (expense)		1.1	(0.3)	(0.2)	(0.2)	(0.1)	(0.1)	(66.7)	0.0	—	(0.1)	(50.0)	0.4	—
Other expense		(3.5)	(1.1)	(0.4)	(1.1)	(1.7)	(0.6)	(45.5)	(1.5)	+275.0	(2.1)	+90.9	(3.2)	+88.2
Profit before taxes		78.1	25.3	49.5	77.3	101.3	42.1	+66.4	70.1	+41.6	101.0	+30.7	127.5	+25.9
(% of Revenues)		15.9	20.2	19.6	19.9	19.0	28.6	—	24.6	—	23.7	—	22.0	—
Income taxes		(21.3)	(6.3)	(10.7)	(17.6)	(24.5)	(10.9)	+73.0	(17.5)	+63.6	(26.4)	+50.0	(30.2)	+23.3
Net income		56.8	18.9	38.8	59.7	76.7	31.2	+65.1	52.6	+35.6	74.6	+25.0	97.3	+26.9
(% of Revenues)		11.5	15.1	15.3	15.4	14.4	21.2	—	18.4	—	17.5	—	16.8	—
Attributable to														
Chugai shareholders		56.1	18.7	38.4	59.0	75.9	31.0	+65.8	52.2	+35.9	74.0	+25.4	96.7	+27.4
Non-controlling interests		0.8	0.2	0.4	0.7	0.8	0.3	+50.0	0.4	0.0	0.5	(28.6)	0.6	(25.0)
Weighted average number of shares in issue used to calculate diluted earnings per share (Millions of shares)		547	547	547	547	547	548	+0.2	548	+0.2	548	+0.2	548	+0.2
Core earnings per share (diluted) (yen)		102.50	34.22	70.10	107.80	138.68	56.52	+65.2	95.27	+35.9	135.14	+25.4	176.42	+27.2
Core payout ratio (%)		50.7	44.7				48.7							
Dividend per share (Full year) (yen)		52	62				86							
Dividend per share (Half year) (yen)		26	29				31							

Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

Statements of revenues (QTR)

(Billions of yen)

	Actual				Actual							
	FY2017				FY2018							
	1-3	4-6	7-9	10-12	1-3	Change (%)	4-6	Change (%)	7-9	Change (%)	10-12	Change (%)
	QTR	QTR	QTR	QTR	QTR		QTR		QTR		QTR	
Sales	118.1	118.7	127.9	134.5	124.7	+5.6	130.8	+10.2	133.1	+4.1	139.1	+3.4
Excl. Tamiflu	110.8	117.9	126.1	127.7	116.3	+5.0	130.8	+10.9	132.7	+5.2	137.3	+7.5
Domestic	85.1	97.9	97.9	107.5	84.5	(0.7)	98.3	+0.4	99.2	+1.3	107.3	(0.2)
Oncology	49.3	57.1	57.2	62.3	48.6	(1.4)	57.0	(0.2)	57.7	+0.9	62.3	0.0
Avastin	20.5	23.5	23.5	25.6	21.0	+2.4	24.4	+3.8	24.1	+2.6	26.1	+1.9
Herceptin	7.5	8.6	8.4	9.0	6.8	(9.3)	7.0	(18.6)	6.8	(19.0)	7.5	(16.9)
Rituxan	7.0	8.5	8.7	9.3	6.2	(11.4)	5.7	(32.9)	5.2	(40.2)	4.2	(54.5)
Alecensa	3.3	4.1	4.4	5.0	4.0	+21.2	5.4	+31.7	5.3	+20.5	5.9	+17.2
Perjeta	2.9	3.4	3.5	3.8	3.2	+10.3	3.8	+11.8	3.9	+11.4	5.2	+36.3
Xeloda	2.8	3.1	3.0	3.3	2.8	0.0	3.3	+6.5	3.1	+3.3	3.3	0.0
Tarceva	2.4	2.7	2.6	2.8	1.9	(20.8)	2.5	(7.4)	2.1	(19.2)	1.8	(34.6)
Kadcyla	1.8	2.0	2.0	2.2	1.8	0.0	2.2	+10.0	2.2	+10.0	2.3	+5.5
Tecentriq	–	–	–	–	–	–	1.7	–	3.3	–	4.1	–
Alaglio	–	–	–	0.0	0.1	–	0.1	–	0.1	–	0.1	–
Gazyva	–	–	–	–	–	–	–	–	0.1	–	0.5	–
Zelboraf	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other products	1.0	1.2	1.2	1.3	0.8	(20.0)	1.0	(16.7)	1.4	+16.7	1.4	+8.5
Bone and joint diseases	20.4	23.2	23.4	26.3	21.6	+5.9	25.4	+9.5	25.4	+8.5	28.0	+6.6
Actemra	7.0	8.2	8.4	9.5	8.0	+14.3	9.6	+17.1	9.8	+16.7	10.7	+12.8
Edirol	6.3	7.4	7.4	8.5	7.0	+11.1	8.2	+10.8	8.3	+12.2	9.4	+10.8
Bonviva	1.8	2.2	2.2	2.5	2.1	+16.7	2.4	+9.1	2.3	+4.5	2.6	+4.4
Suvenyl	1.9	2.3	2.2	2.4	1.7	(10.5)	2.0	(13.0)	1.9	(13.6)	2.1	(11.7)
Other products	3.4	3.2	3.2	3.3	2.9	(14.7)	3.1	(3.1)	3.1	(3.1)	3.2	(3.9)
Renal diseases	8.3	10.1	10.0	11.0	8.0	(3.6)	9.0	(10.9)	9.3	(7.0)	10.0	(8.7)
Mircera	4.9	6.1	6.2	6.8	4.9	0.0	5.8	(4.9)	5.9	(4.8)	6.5	(4.3)
Oxarol	1.7	2.1	2.1	2.2	1.7	0.0	1.8	(14.3)	1.8	(14.3)	2.0	(9.5)
Other products	1.7	1.9	1.7	1.9	1.4	(17.6)	1.4	(26.3)	1.5	(11.8)	1.5	(18.9)
Others	7.1	7.5	7.4	7.9	6.2	(12.7)	6.8	(9.3)	6.9	(6.8)	6.9	(12.7)
CellCept	1.9	2.2	2.2	2.5	2.0	+5.3	2.3	+4.5	2.2	0.0	2.4	(2.8)
Hemlibra	–	–	–	–	–	–	0.5	–	1.0	–	1.5	–
Other products	5.2	5.3	5.2	5.4	4.2	(19.2)	4.0	(24.5)	3.6	(30.8)	3.0	(45.2)
Overseas	25.6	20.0	28.1	20.2	31.9	+24.6	32.6	+63.0	33.5	+19.2	30.0	+48.7
Actemra	18.0	13.1	17.6	12.2	23.4	+30.0	21.5	+64.1	19.6	+11.4	16.1	+32.2
To Roche	17.7	12.7	17.2	11.8	23.0	+29.9	21.0	+65.4	19.1	+11.0	15.6	+32.2
Alecensa	3.6	1.8	4.8	3.7	3.8	+5.6	6.5	+261.1	9.3	+93.8	10.0	+170.3
To Roche	3.6	1.8	4.8	3.7	3.7	+2.8	6.3	+250.0	9.1	+89.6	9.8	+165.1
Neutrogen	2.9	3.1	3.2	3.1	3.0	+3.4	2.7	(12.9)	3.0	(6.3)	2.4	(21.3)
Hemlibra	–	1.0	1.8	0.3	0.7	–	0.5	(50.0)	0.8	(55.6)	0.4	+16.7
Akynzeo	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.0	0.1	0.0
Aloxi	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other products	1.1	0.9	0.6	0.8	1.0	(9.1)	1.3	+44.4	0.8	+33.3	1.0	+21.3
Tamiflu	7.4	0.8	1.9	6.8	8.4	+13.5	0.0	(100.0)	0.4	(78.9)	1.8	(73.4)
Ordinary use	6.1	0.2	0.0	5.6	8.3	+36.1	0.0	(100.0)	0.0	0.0	1.8	(67.7)
Govt. stockpiles etc.	1.3	0.6	1.8	1.2	0.1	(92.3)	–	(100.0)	0.4	(77.8)	–	(100.0)
Royalties and other operating income	7.3	8.6	6.9	12.0	22.7	+211.0	6.8	(20.9)	8.2	+18.8	14.2	+18.3
Revenues	125.5	127.3	134.9	146.6	147.4	+17.5	137.7	+8.2	141.3	+4.7	153.4	+4.6
Domestic	95.7	100.5	100.3	114.4	110.6	+15.6	99.7	(0.8)	102.2	+1.9	109.0	(4.7)
Overseas	29.7	26.8	34.5	32.2	36.9	+24.2	37.9	+41.4	39.2	+13.6	44.3	+37.6

Statements of revenues (YTD)

(Billions of yen)

	Actual FY2016 1-12 YTD	Actual FY2017 1-3 YTD				Actual FY2018 1-3 YTD							
		1-3 YTD	Change (%)	1-6 YTD	Change (%)	1-9 YTD	Change (%)	1-12 YTD	Change (%)	1-3 YTD	Change (%)	1-6 YTD	Change (%)
Sales	472.7	118.1	236.8	364.8	499.3	124.7	+5.6	255.6	+7.9	388.7	+6.6	527.8	+5.7
Excl.Tamiflu	459.2	110.8	228.7	354.8	482.4	116.3	+5.0	247.2	+8.1	379.8	+7.0	517.2	+7.2
Domestic	379.7	85.1	183.0	281.0	388.4	84.5	(0.7)	182.7	(0.2)	281.9	+0.3	389.2	+0.2
Oncology	220.3	49.3	106.3	163.5	225.9	48.6	(1.4)	105.7	(0.6)	163.3	(0.1)	225.7	(0.1)
Avastin	92.1	20.5	44.0	67.6	93.1	21.0	+2.4	45.4	+3.2	69.5	+2.8	95.6	+2.7
Herceptin	34.1	7.5	16.2	24.6	33.6	6.8	(9.3)	13.8	(14.8)	20.6	(16.3)	28.1	(16.4)
Rituxan	32.1	7.0	15.4	24.1	33.4	6.2	(11.4)	11.9	(22.7)	17.0	(29.5)	21.3	(36.2)
Alecensa	11.9	3.3	7.4	11.7	16.7	4.0	+21.2	9.4	+27.0	14.7	+25.6	20.6	+23.4
Perjeta	11.9	2.9	6.3	9.8	13.6	3.2	+10.3	7.0	+11.1	11.0	+12.2	16.1	+18.4
Xeloda	12.3	2.8	5.9	8.9	12.2	2.8	0.0	6.1	+3.4	9.2	+3.4	12.5	+2.5
Tarceva	11.5	2.4	5.2	7.7	10.5	1.9	(20.8)	4.4	(15.4)	6.5	(15.6)	8.3	(21.0)
Kadcyla	8.3	1.8	3.7	5.8	8.0	1.8	0.0	4.0	+8.1	6.2	+6.9	8.5	+6.3
Tecentriq	-	-	-	-	-	-	-	1.7	-	5.0	-	9.1	-
Alaglio	-	-	-	-	0.0	0.1	-	0.1	-	0.2	-	0.3	-
Gazyva	-	-	-	-	-	-	-	-	-	0.1	-	0.6	-
Zelboraf	0.4	0.0	0.1	0.1	0.1	0.0	0.0	0.0	(100.0)	0.0	(100.0)	0.1	0.0
Other products	5.8	1.0	2.2	3.3	4.6	0.8	(20.0)	1.8	(18.2)	3.2	(3.0)	4.6	0.0
Bone and joint diseases	86.1	20.4	43.7	67.1	93.3	21.6	+5.9	47.0	+7.6	72.4	+7.9	100.5	+7.7
Actemra	30.2	7.0	15.2	23.6	33.1	8.0	+14.3	17.7	+16.4	27.4	+16.1	38.2	+15.4
Ediol	26.7	6.3	13.7	21.1	29.6	7.0	+11.1	15.2	+10.9	23.4	+10.9	32.9	+11.1
Bonviva	7.3	1.8	4.0	6.2	8.7	2.1	+16.7	4.4	+10.0	6.8	+9.7	9.4	+8.0
Suvenyl	9.3	1.9	4.2	6.4	8.8	1.7	(10.5)	3.7	(11.9)	5.7	(10.9)	7.8	(11.4)
Other products	12.6	3.4	6.6	9.8	13.1	2.9	(14.7)	6.0	(9.1)	9.1	(7.1)	12.3	(6.1)
Renal diseases	41.1	8.3	18.4	28.3	39.3	8.0	(3.6)	17.0	(7.6)	26.3	(7.1)	36.3	(7.6)
Mircera	24.2	4.9	11.0	17.2	23.9	4.9	0.0	10.6	(3.6)	16.6	(3.5)	23.1	(3.3)
Oxarol	9.1	1.7	3.8	5.9	8.2	1.7	0.0	3.5	(7.9)	5.3	(10.2)	7.3	(11.0)
Other products	7.8	1.7	3.5	5.3	7.2	1.4	(17.6)	2.8	(20.0)	4.3	(18.9)	5.9	(18.1)
Others	32.2	7.1	14.6	22.0	29.9	6.2	(12.7)	13.0	(11.0)	19.9	(9.5)	26.8	(10.4)
CellCept	7.9	1.9	4.1	6.4	8.9	2.0	+5.3	4.3	+4.9	6.6	+3.1	9.0	+1.1
Hemlibra	-	-	-	-	-	-	-	0.5	-	1.5	-	3.0	-
Other products	24.3	5.2	10.5	15.7	21.0	4.2	(19.2)	8.3	(21.0)	11.9	(24.2)	14.9	(29.0)
Overseas	79.5	25.6	45.7	73.8	94.0	31.9	+24.6	64.5	+41.1	97.9	+32.7	127.9	+36.1
Actemra	60.3	18.0	31.1	48.7	60.9	23.4	+30.0	44.9	+44.4	64.4	+32.2	80.6	+32.3
To Roche	59.1	17.7	30.4	47.6	59.4	23.0	+29.9	44.1	+45.1	63.1	+32.6	78.7	+32.5
Alecensa	3.7	3.6	5.5	10.2	13.9	3.8	+5.6	10.3	+87.3	19.5	+91.2	29.5	+112.2
To Roche	3.7	3.6	5.5	10.2	13.9	3.7	+2.8	10.0	+81.8	19.1	+87.3	28.9	+107.9
Neutrogen	12.2	2.9	5.9	9.2	12.3	3.0	+3.4	5.7	(3.4)	8.7	(5.4)	11.1	(9.8)
Hemlibra	-	-	1.0	2.8	3.1	0.7	-	1.2	+20.0	2.0	(28.6)	2.3	(25.8)
Akynzeo	0.1	0.1	0.1	0.2	0.3	0.1	0.0	0.1	0.0	0.2	0.0	0.3	0.0
Aloxi	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0
Other products	3.0	1.1	2.0	2.6	3.5	1.0	(9.1)	2.3	+15.0	3.0	+15.4	4.0	+14.3
Tamiflu	13.5	7.4	8.2	10.0	16.9	8.4	+13.5	8.4	+2.4	8.9	(11.0)	10.7	(36.7)
Ordinary use	12.0	6.1	6.3	6.3	11.9	8.3	+36.1	8.3	+31.7	8.3	+31.7	10.1	(15.1)
Govt. stockpiles etc.	1.5	1.3	1.9	3.7	5.0	0.1	(92.3)	0.1	(94.7)	0.5	(86.5)	0.5	(90.0)
Royalties and other operating income	19.1	7.3	15.9	22.9	34.9	22.7	+211.0	29.5	+85.5	37.7	+64.6	51.9	+48.7
Revenues	491.8	125.5	252.8	387.6	534.2	147.4	+17.5	285.1	+12.8	426.4	+10.0	579.8	+8.5
Domestic	395.1	95.7	196.2	296.5	410.9	110.6	+15.6	210.3	+7.2	312.5	+5.4	421.5	+2.6
Overseas	96.6	29.7	56.6	91.1	123.3	36.9	+24.2	74.8	+32.2	114.0	+25.1	158.3	+28.4

Core results (YTD) New format

(Billions of yen)

	Actual	Actual								Forecast (Jan 31st announced)	
	FY2017	FY2018								FY2019	
	1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)
	YTD	YTD		YTD		YTD		YTD		YTD	
Revenues	534.2	147.4	+17.5	285.1	+12.8	426.4	+10.0	579.8	+8.5	592.5	+2.2
Sales	499.3	124.7	+5.6	255.6	+7.9	388.7	+6.6	527.8	+5.7	528.0	0.0
Domestic	405.3	92.9	+0.4	191.1	(0.1)	290.8	(0.1)	399.9	(1.3)	389.1	(2.7)
Overseas	94.0	31.9	+24.6	64.5	+41.1	97.9	+32.7	127.9	+36.1	138.9	+8.6
Royalties and other operating income	34.9	22.7	+211.0	29.5	+85.5	37.7	+64.6	51.9	+48.7	64.5	+24.3
Royalty and profit-sharing income	17.2	5.0	+28.2	10.1	+23.2	15.8	+26.4	24.1	+40.1	53.5	+122.0
Other operating income	17.7	17.7	+420.6	19.5	+150.0	21.9	+112.6	27.9	+57.6	11.0	(60.6)
Cost of sales	(252.9)	(63.5)	+4.3	(128.6)	+6.5	(194.3)	+4.7	(261.9)	+3.6	(252.5)	(3.6)
(% of Sales)	50.7	50.9	—	50.3	—	50.0	—	49.6	—	47.8	—
Gross profit	281.3	83.9	+29.9	156.6	+18.7	232.1	+14.8	317.9	+13.0	340.0	+7.0
(% of Revenues)	52.7	56.9	—	54.9	—	54.4	—	54.8	—	57.4	—
Operating expenses	(178.1)	(41.1)	+8.4	(84.9)	+3.8	(128.9)	+4.5	(187.6)	+5.3	(197.0)	+5.0
(% of Revenues)	33.3	27.9	—	29.8	—	30.2	—	32.4	—	33.2	—
Marketing and distribution	(72.8)	(15.9)	+3.2	(33.2)	+3.1	(50.4)	+2.4	(73.7)	+1.2		
(% of Revenues)	13.6	10.8	—	11.6	—	11.8	—	12.7	—		
Research and development	(88.9)	(20.9)	+8.9	(44.0)	+3.8	(66.3)	+4.9	(94.2)	+6.0	(102.0)	+8.3
(% of Revenues)	16.6	14.2	—	15.4	—	15.5	—	16.2	—	17.2	—
General and administration	(16.3)	(4.3)	+30.3	(7.8)	+8.3	(12.2)	+10.9	(19.7)	+20.9		
(% of Revenues)	3.1	2.9	—	2.7	—	2.9	—	3.4	—		
Operating profit	103.2	42.8	+60.3	71.6	+42.6	103.3	+31.3	130.3	+26.3	143.0	+9.7
(% of Revenues)	19.3	29.0	—	25.1	—	24.2	—	22.5	—	24.1	—
Financing costs	(0.1)	(0.0)	0.0	(0.1)	0.0	(0.1)	0.0	(0.1)	0.0		
Other financial income (expense)	(0.1)	(0.1)	(66.7)	0.0	—	(0.1)	(50.0)	0.4	—		
Other expense	(1.7)	(0.6)	(45.5)	(1.5)	+275.0	(2.1)	+90.9	(3.2)	+88.2		
Profit before taxes	101.3	42.1	+66.4	70.1	+41.6	101.0	+30.7	127.5	+25.9		
(% of Revenues)	19.0	28.6	—	24.6	—	23.7	—	22.0	—		
Income taxes	(24.5)	(10.9)	+73.0	(17.5)	+63.6	(26.4)	+50.0	(30.2)	+23.3		
Net income	76.7	31.2	+65.1	52.6	+35.6	74.6	+25.0	97.3	+26.9		
(% of Revenues)	14.4	21.2	—	18.4	—	17.5	—	16.8	—		
Attributable to											
Chugai shareholders	75.9	31.0	+65.8	52.2	+35.9	74.0	+25.4	96.7	+27.4		
Non-controlling interests	0.8	0.3	+50.0	0.4	0.0	0.5	(28.6)	0.6	(25.0)		
Weighted average number of shares in issue used to calculate diluted earnings per share (Millions of shares)	547	548	+0.2	548	+0.2	548	+0.2	548	+0.2		
Core earnings per share (diluted) (yen)	138.68	56.52	+65.2	95.27	+35.9	135.14	+25.4	176.42	+27.2	198.00	+12.2
Core payout ratio (%)	44.7							48.7		48.5	—
Dividend per share (Full year) (yen)	62							86		96	—
Dividend per share (Half year) (yen)	29							31		48	—

Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

Sales of Tamiflu are included in "Domestic Sales" in this new format.

The breakdown of "Royalties and other operating income" is disclosed separately as "Royalty and profit-sharing income" and "Other operating income" in this new format.

Statements of revenues (YTD) New format

(Billions of yen)

		Actual	Actual								Forecast (Jan 31st announced)		
			FY2018								FY2019		
			1-12	1-3	Change (%)	1-6	Change (%)	1-9	Change (%)	1-12	Change (%)	1-12	Change (%)
			YTD	YTD		YTD		YTD		YTD		YTD	
Sales		499.3	124.7	+5.6	255.6	+7.9	388.7	+6.6	527.8	+5.7	528.0	0.0	
Domestic		405.3	92.9	+0.4	191.1	(0.1)	290.8	(0.1)	399.9	(1.3)	389.1	(2.7)	
Oncology		225.9	48.6	(1.4)	105.7	(0.6)	163.3	(0.1)	225.7	(0.1)	215.9	(4.3)	
Avastin		93.1	21.0	+2.4	45.4	+3.2	69.5	+2.8	95.6	+2.7	89.4	(6.5)	
Alecensa		16.7	4.0	+21.2	9.4	+27.0	14.7	+25.6	20.6	+23.4	25.1	+21.8	
Herceptin		33.6	6.8	(9.3)	13.8	(14.8)	20.6	(16.3)	28.1	(16.4)	24.0	(14.6)	
Perjeta		13.6	3.2	+10.3	7.0	+11.1	11.0	+12.2	16.1	+18.4	21.2	+31.7	
Rituxan		33.4	6.2	(11.4)	11.9	(22.7)	17.0	(29.5)	21.3	(36.2)	13.5	(36.6)	
Tecentriq		—	—	—	1.7	—	5.0	—	9.1	—	13.1	+44.0	
Xeloda		12.2	2.8	0.0	6.1	+3.4	9.2	+3.4	12.5	+2.5	9.4	(24.8)	
Kadcyla		8.0	1.8	0.0	4.0	+8.1	6.2	+6.9	8.5	+6.3	9.1	+7.1	
Tarceva		10.5	1.9	(20.8)	4.4	(15.4)	6.5	(15.6)	8.3	(21.0)	5.6	(32.5)	
Gazyva		—	—	—	—	—	0.1	—	0.6	—	1.8	+200.0	
Alaglio		0.0	0.1	—	0.1	—	0.2	—	0.3	—	0.4	+33.3	
Other products		4.7	0.8	(20.0)	1.8	(18.2)	3.3	(2.9)	4.7	0.0	3.3	(29.8)	
Bone and joint diseases		93.3	21.6	+5.9	47.0	+7.6	72.4	+7.9	100.5	+7.7	103.1	+2.6	
Actemra		33.1	8.0	+14.3	17.7	+16.4	27.4	+16.1	38.2	+15.4	38.2	0.0	
Edirol		29.6	7.0	+11.1	15.2	+10.9	23.4	+10.9	32.9	+11.1	35.3	+7.3	
Bonviva		8.7	2.1	+16.7	4.4	+10.0	6.8	+9.7	9.4	+8.0	10.9	+16.0	
Suvenyl		8.8	1.7	(10.5)	3.7	(11.9)	5.7	(10.9)	7.8	(11.4)	6.1	(21.8)	
Other products		13.1	2.9	(14.7)	6.0	(9.1)	9.1	(7.1)	12.3	(6.1)	12.6	+2.4	
Renal diseases		39.3	8.0	(3.6)	17.0	(7.6)	26.3	(7.1)	36.3	(7.6)	31.8	(12.4)	
Mircera		23.9	4.9	0.0	10.6	(3.6)	16.6	(3.5)	23.1	(3.3)	20.5	(11.3)	
Oxarol		8.2	1.7	0.0	3.5	(7.9)	5.3	(10.2)	7.3	(11.0)	5.9	(19.2)	
Other products		7.2	1.4	(17.6)	2.8	(20.0)	4.3	(18.9)	5.9	(18.1)	5.3	(10.2)	
Others		46.8	14.6	+0.7	21.5	(5.7)	28.8	(10.0)	37.5	(19.9)	38.3	+2.1	
Hemlibra		—	—	—	0.5	—	1.5	—	3.0	—	12.9	+330.0	
CellCept		8.9	2.0	+5.3	4.3	+4.9	6.6	+3.1	9.0	+1.1	9.0	0.0	
Tamiflu(Ordinary use)		11.9	8.3	+36.1	8.3	+31.7	8.3	+31.7	10.1	(15.1)	3.4	(66.3)	
Tamiflu(Govt. stockpiles etc.)		5.0	0.1	(92.3)	0.1	(94.7)	0.5	(86.5)	0.5	(90.0)	3.2	+540.0	
Other products		21.0	4.2	(19.2)	8.3	(21.0)	11.9	(24.2)	14.9	(29.0)	9.8	(34.2)	
Overseas		94.0	31.9	+24.6	64.5	+41.1	97.9	+32.7	127.9	+36.1	138.9	+8.6	
Actemra		60.9	23.4	+30.0	44.9	+44.4	64.4	+32.2	80.6	+32.3	84.6	+5.0	
To Roche		59.4	23.0	+29.9	44.1	+45.1	63.1	+32.6	78.7	+32.5	82.7	+5.1	
Alecensa		13.9	3.8	+5.6	10.3	+87.3	19.5	+91.2	29.5	+112.2	36.6	+24.1	
To Roche		13.9	3.7	+2.8	10.0	+81.8	19.1	+87.3	28.9	+107.9	36.0	+24.6	
Neutrogen		12.3	3.0	+3.4	5.7	(3.4)	8.7	(5.4)	11.1	(9.8)	9.5	(14.4)	
Hemlibra		3.1	0.7	—	1.2	+20.0	2.0	(28.6)	2.3	(25.8)	2.4	+4.3	
Other products		3.9	1.0	(9.1)	2.4	+9.1	3.3	+13.8	4.4	+12.8	5.8	+31.8	
Royalties and other operating income		34.9	22.7	+211.0	29.5	+85.5	37.7	+64.6	51.9	+48.7	64.5	+24.3	
Royalty and profit-sharing income		17.2	5.0	+28.2	10.1	+23.2	15.8	+26.4	24.1	+40.1	53.5	+122.0	
Other operating income		17.7	17.7	+420.6	19.5	+150.0	21.9	+112.6	27.9	+57.6	11.0	(60.6)	
Revenues		534.2	147.4	+17.5	285.1	+12.8	426.4	+10.0	579.8	+8.5	592.5	+2.2	
Domestic		410.9	110.6	+15.5	210.3	+7.2	312.5	+5.4	421.5	+2.6	390.9	(7.3)	
Overseas		123.3	36.9	+24.1	74.8	+32.1	114.0	+25.1	158.3	+28.4	201.6	+27.4	

Sales of Tamiflu are included in "Others" in this new format.

The breakdown of "Royalties and other operating income" is disclosed separately as "Royalty and profit-sharing income" and "Other operating income" in this new format.

Financial position

(Billions of yen)

	Actual	Actual					Actual									
	FY2016	FY2017					FY2018									
	Dec. 31	Mar. 31	Jun. 30	Sep. 30	Dec. 31	Mar. 31	vs. Mar. 31, 2017	vs. Dec. 31, 2017	Jun. 30	vs. Jun. 30, 2017	vs. Dec. 31, 2017	Sep. 30	vs. Sep. 30, 2017	vs. Dec. 31, 2017	Dec. 31	vs. Dec. 31, 2017
Trade accounts receivable	140.7	125.2	128.9	146.2	148.5	137.1	11.9	(11.4)	140.6	11.7	(7.9)	145.7	(0.5)	(2.8)	150.8	2.3
Inventories	185.4	189.5	188.3	177.7	169.1	168.1	(21.4)	(1.0)	170.0	(18.3)	0.9	163.8	(13.9)	(5.3)	159.4	(9.7)
Trade accounts payable	(42.5)	(45.0)	(50.6)	(38.1)	(38.4)	(48.7)	(3.7)	(10.3)	(46.2)	4.4	(7.8)	(42.3)	(4.2)	(3.9)	(35.9)	2.5
Other net working capital	(25.2)	(26.3)	(19.6)	(22.1)	(28.4)	(24.7)	1.6	3.7	(18.2)	1.4	10.2	(28.7)	(6.6)	(0.3)	(39.1)	(10.7)
Net working capital	258.5	243.3	247.0	263.7	250.7	231.8	(11.5)	(18.9)	246.3	(0.7)	(4.4)	238.5	(25.2)	(12.2)	235.1	(15.6)
Property, plant and equipment	157.1	163.3	171.3	170.5	171.6	174.6	11.3	3.0	179.2	7.9	7.6	187.6	17.1	16.0	222.4	50.8
Intangible assets	19.3	20.3	19.6	21.2	21.1	17.9	(2.4)	(3.2)	18.1	(1.5)	(3.0)	19.8	(1.4)	(1.3)	22.7	1.6
Other long-term assets – net	(3.7)	(3.1)	(2.9)	(3.2)	(3.1)	13.2	16.3	16.3	12.4	15.3	15.5	16.9	20.1	20.0	25.1	28.2
Long-term net operating assets	172.7	180.5	188.1	188.4	189.5	205.7	25.2	16.2	209.6	21.5	20.1	224.3	35.9	34.8	270.1	80.6
Net operating assets	431.1	423.7	435.0	452.2	440.2	437.5	13.8	(2.7)	455.9	20.9	15.7	462.7	10.5	22.5	505.3	65.1
Debt	(0.6)	(0.6)	(0.4)	(0.4)	(0.3)	(0.3)	0.3	0.0	(0.3)	0.1	0.0	(0.2)	0.2	0.1	(0.2)	0.1
Marketable securities	110.2	108.4	110.2	110.9	104.0	113.8	5.4	9.8	119.9	9.7	15.9	122.9	12.0	18.9	102.5	(1.5)
Cash and cash equivalents	95.4	103.7	110.7	97.6	139.1	152.8	49.1	13.7	154.6	43.9	15.5	146.0	48.4	6.9	146.9	7.8
Net cash	204.9	211.4	220.5	208.1	242.8	266.3	54.9	23.5	274.2	53.7	31.4	268.6	60.5	25.8	249.2	6.4
Other non-operating assets – net	10.5	12.6	12.6	14.3	9.9	7.6	(5.0)	(2.3)	1.5	(11.1)	(8.4)	8.3	(6.0)	(1.6)	2.1	(7.8)
Net non-operating assets	215.4	224.1	233.1	222.4	252.7	273.9	49.8	21.2	275.7	42.6	23.0	276.9	54.5	24.2	251.3	(1.4)
Total net assets	646.5	647.8	668.2	674.6	692.9	711.3	63.5	18.4	731.7	63.5	38.8	739.6	65.0	46.7	756.5	63.6
Total net assets																
Total assets	806.3	798.2	821.7	817.9	852.5	852.9	54.7	0.4	873.3	51.6	20.8	890.8	72.9	38.3	919.5	67.0
Total liabilities	(159.8)	(150.4)	(153.5)	(143.4)	(159.6)	(141.5)	8.9	18.1	(141.7)	11.8	17.9	(151.2)	(7.8)	8.4	(163.0)	(3.4)
Attributable to																
Chugai shareholders	645.5	647.0	667.6	673.8	691.9	710.1	63.1	18.2	731.2	63.6	39.3	739.0	65.2	47.1	755.9	64.0
Non-controlling interests	1.0	0.8	0.5	0.8	1.0	1.2	0.4	0.2	0.5	0.0	(0.5)	0.7	(0.1)	(0.3)	0.7	(0.3)

Trade accounts receivable: trade receivable and notes receivable

Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-term assets-net: long-term prepaid expenses, long-term provisions etc.

Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc.

Net operating assets (NOA) and Net assets:

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, "Presentation of Financial Statements." On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets of IFRS have been excluded, as the Core results concept only applies to the income statement.

Net operating assets (NOA):

Net operating assets allow for an assessment of the Group's operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, intangible assets etc. minus provisions.

IFRS 15 'Revenues from Contracts with Customers'

With the application of IFRS 15 'Revenue from Contracts with Customers,' deferred income of ¥10.6 billion after tax effect, which was included in net working capital and long-term net operating assets at the beginning of the year, has been presented as retained earnings.

Cash flows

(Billions of yen)

	Actual	Actual					Actual			
	FY2016	FY2017					FY2018			
	1-12	1-3	1-6	1-9	1-12		1-3	1-6	1-9	1-12
	YTD	YTD	YTD	YTD	YTD		YTD	YTD	YTD	YTD
Operating profit – IFRS basis	76.9	26.3	47.1	76.2	98.9		38.4	66.6	97.9	124.3
Depreciation and impairment of property, plant and equipment	14.8	3.6	7.2	10.8	14.6		3.7	7.4	11.1	14.6
Amortization and impairment of intangible assets	4.0	0.4	3.3	3.8	5.8		4.6	5.5	5.9	6.8
Other cash adjustment on operating profit	2.8	0.4	(0.7)	(0.4)	1.7		0.4	1.0	1.5	1.6
Operating profit, net of operating cash adjustments	98.5	30.8	56.9	90.5	121.0		47.1	80.4	116.4	147.4
(Increase) decrease in trade accounts receivable	(6.4)	15.5	11.9	(5.4)	(7.6)		11.4	7.8	2.8	(2.4)
(Increase) decrease in inventories	(26.3)	(4.3)	(0.4)	11.8	21.1		0.5	(1.9)	4.5	14.2
Increase (decrease) in trade accounts payable	1.5	2.5	8.1	(4.5)	(4.2)		10.3	7.8	3.9	(2.4)
Change in other net working capital etc.	(5.0)	(1.6)	(7.9)	2.5	5.2		(1.7)	(10.8)	(8.5)	(4.8)
Total (increase) decrease in net working capital etc.	(36.2)	12.2	11.6	4.4	14.5		20.5	2.9	2.7	4.5
Investment in property, plant and equipment	(30.1)	(5.3)	(17.3)	(29.8)	(32.9)		(9.9)	(15.1)	(23.8)	(71.8)
Investment in intangible assets	(6.2)	(4.0)	(7.4)	(8.9)	(11.6)		(1.4)	(2.4)	(4.6)	(5.9)
Operating free cash flow	26.0	33.6	43.8	56.2	91.0		56.3	65.9	90.7	74.3
as % of revenues	5.3%	26.8%	17.3%	14.5%	17.0%		38.2%	23.1%	21.3%	12.8%
Treasury activities (interest income/expenses, foreign exchange gains/losses etc.)	3.7	(1.3)	(0.6)	1.3	1.6		3.4	3.7	3.4	4.3
Settlement for transfer pricing taxation	–	–	(3.9)	(4.6)	(5.2)		(0.6)	(1.5)	(2.1)	(3.2)
Tax paid	(25.3)	(10.9)	(11.0)	(21.9)	(22.7)		(16.8)	(17.1)	(31.3)	(31.6)
Free cash flow	4.3	21.4	28.3	31.1	64.7		42.3	50.9	60.7	43.7
Dividends paid	(32.8)	(14.4)	(14.6)	(30.9)	(31.0)		(17.9)	(18.0)	(34.9)	(35.8)
Transaction in own equity instruments	0.5	0.3	0.5	0.6	0.9		0.2	0.5	0.9	1.0
Net effect of currency translation on net cash	(2.6)	(0.7)	1.4	2.5	3.2		(1.0)	(2.0)	(0.8)	(2.5)
Net change in net cash	(30.5)	6.5	15.6	3.2	37.9		23.5	31.4	25.8	6.4

Other cash adjustment on operating profit: adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) (including proceeds from the sales of assets and reserve payments)

Operating free cash flow (Operating FCF): pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to “operating profit, net of operating cash adjustments,” which shows the company’s cash generation ability from operating activities.

Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.

Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt are included.

The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent.

Free cash flow (FCF):

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

Performance indicators

	Units	Actual	Actual					Actual				Forecast (Jan 31st announced)
		FY2016	FY2017					FY2018				FY2019
		1-12	1-3	1-6	1-9	1-12	1-3	1-6	1-9	1-12	1-12	1-12
		As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Mar. 31	As of Jun. 30	As of Sep. 30	As of Dec. 31	As of Dec. 31	As of Dec. 31
Ratio of net income to equity attributable to Chugai shareholders (ROE)	%	8.4	2.9	5.5	8.7	10.9	4.0	6.8	9.8	12.8		
Ratio of profit before taxes to total assets (ROA)	%	9.3	3.1	5.7	9.2	11.7	4.4	7.5	11.0	13.7		
Ratio of equity attributable to Chugai shareholders	%	80.1	81.1	81.3	82.4	81.2	83.3	83.7	83.0	82.2		
Equity per share attributable to Chugai shareholders (BPS)	Yen	1,181.67	1,184.11	1,221.41	1,232.55	1,265.46	1,298.53	1,336.49	1,350.49	1,381.26		
Ratio of dividends to equity attributable to Chugai shareholders (DOE)	%	4.5	5.1					6.5				
Core return on invested capital (Core ROIC)	%	14.6	4.8	9.1	13.8	18.1	7.3	12.1	17.0	21.2		
Core return on net operating assets (Core RONOA)	%	14.0	4.4	9.0	13.5	17.6	7.1	11.7	16.5	20.6		
Cash conversion cycle (CCC)	Months	10.5	10.3	10.1	10.3	9.7	8.9	9.1	9.0	9.1		
Net cash turnover period	Months	5.0	5.1	5.2	4.8	5.5	5.4	5.8	5.7	5.2		
Number of employees		7,245	7,224	7,384	7,375	7,372	7,331	7,490	7,475	7,432		
Investment on property, plant and equipment	Billions of yen	19.4	10.0	22.9	27.4	34.3	7.0	14.5	27.9	71.8	56.0	
Depreciation	Billions of yen	14.8	3.6	7.2	10.8	14.5	3.7	7.4	11.0	14.6	15.0	
Investment on intangible assets	Billions of yen	9.9				8.0				8.5		
Amortization	Billions of yen	1.6				1.8				2.0		

Core ROIC: Core net operating profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes.)

Core RONOA: Core net income / Net operating assets

CCC: [Trade accounts receivable/Sales + (Inventories - Trade accounts payable)/Cost of sales]* passed months

Net cash turnover period: Net cash/Revenue* passed months

Ratio of net income to equity attributable to Chugai shareholders (ROE), Ratio of profit before taxes to total assets (ROA), and Core return on net operating assets (Core RONOA) are not annualized.

Major capital investments plan

(The Company)

(Billions of yen)

Facilities (Location)	Description	Planned investment		Fund raising method	Start of construction	Slated completion date
		Total amount	Investment to-date			
Ukima research laboratories (Kita-district, Tokyo)	Construction of a new synthetic research building for strengthening the process development for small and middle molecule active pharmaceutical ingredients	4.5	1.3	Self-financing	May 2018	January 2020

Development pipeline (as of January 31, 2019)

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
<u>Oncology</u>					
GA101 / RG7159	Follicular lymphoma	Launched (18/08)	obinutuzumab Gazyva Injection	Roche Gazyva/Gazyvaro (EU) (Nippon Shinyaku)	Glycoengineered type II anti-CD20 monoclonal antibody
RG1273	Breast cancer (adjuvant) #	Approved (18/10)	pertuzumab Perjeta Injection	Roche Perjeta	HER2 dimerization inhibitory humanized monoclonal antibody
RG7446	Non-small cell lung cancer (NSCLC) [1st line] #	Approved (18/12)	atezolizumab Tecentriq Injection	Roche Tecentriq	Engineered anti-PDL1 monoclonal antibody
	Small cell lung cancer #	Filed (18/12)			
	Breast cancer #	Filed (18/12)			
	NSCLC (adjuvant) #	Phase III Multinational study			
	Urothelial carcinoma #	Phase III Multinational study			
	Muscle invasive urothelial carcinoma (adjuvant) #	Phase III Multinational study			
	Renal cell carcinoma #	Phase III Multinational study			
	Renal cell carcinoma (adjuvant) #	Phase III Multinational study			
	Early breast cancer #	Phase III Multinational study			
	Ovarian cancer #	Phase III Multinational study			
	Prostate cancer #	Phase III Multinational study			
	Hepatocellular carcinoma #	Phase III Multinational study			
	Head and neck carcinoma (adjuvant) #	Phase III Multinational study			

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG6268	Solid tumors [NTRK fusion-positive]	Filed (18/12)	entrectinib	Roche/Nerviano Medical Sciences	ROS1/TRK inhibitor
	NSCLC	Phase II Multinational study	Oral		
RG435	Renal cell carcinoma #	Phase III Multinational study	bevacizumab Avastin Injection	Roche Avastin	Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody
	Hepatocellular carcinoma #	Phase III Multinational study			
RG3502	Breast cancer (adjuvant) #	Phase III Multinational study	trastuzumab emtansine Kadcyla Injection	Roche Kadcyla	Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
RG7440	Prostate cancer	Phase III Multinational study	ipatasertib	Roche/Array BioPharma	AKT inhibitor
	Breast cancer	Phase III Multinational study	Oral		
RG7596	Diffuse large B-cell lymphoma (DLBCL)	Phase III Multinational study	polatuzumab vedotin Injection	Roche	Anti-CD79b antibody-drug conjugate
RG6264	Breast cancer (Fixed-dose combination, subcutaneous injection)	Phase III Multinational study	trastuzumab/pertuzumab Herceptin/Perjeta Injection	Roche Herceptin/Perjeta	Anti-HER2 humanized monoclonal antibody/ HER2 dimerization inhibitory humanized monoclonal antibody
AF802 / RG7853	NSCLC (adjuvant) #	Phase III Multinational study	alectinib Alecensa Oral	In-house Alecensa (Roche)	ALK inhibitor
GC33 / RG7686	Hepatocellular carcinoma	Phase I Multinational study*	codrituzumab Injection	In-house (Roche)	Anti-Glypican-3 humanized monoclonal antibody
CKI27	Solid tumors	Phase I	Oral	In-house	Raf and MEK dual inhibitor
ERY974	Solid tumors	Phase I	Injection	In-house	Anti-Glypican-3/CD3 bispecific antibody
RG7421	Solid tumors	Phase I	cobimetinib Oral	Roche/Exelixis Cotellic	MEK inhibitor

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG7802	Solid tumors	Phase I	cibisatamab Injection	Roche	Anti-CEA/CD3 bispecific antibody
RG7828	Hematologic tumors	Phase I	mosunetuzumab Injection	Roche	Anti-CD20/CD3 bispecific antibody
<u>Bone and Joint Diseases</u>					
ED-71	Osteoporosis	Filed (18/02) China	eldecacitol Edirol Oral	In-house	Activated vitamin D ₃ agent
NRD101	Knee osteoarthritis /Shoulder periarthritis	Phase III China	purified sodium hyaluronate Suvenyl Injection	In-house	Sodium hyaluronate
<u>Renal Diseases</u>					
EOS789	Hyperphosphatemia	Phase I	Oral	In-house	—
<u>Autoimmune Diseases</u>					
MRA / RG1569	Systemic sclerosis #	Phase III Multinational study	tocilizumab Actemra Injection	In-house Actemra/RoActemra (EU) (Roche)	Humanized anti-human IL-6 receptor monoclonal antibody
RG7845	Rheumatoid arthritis	Phase I	fenebrutinib Oral	Roche	BTK inhibitor
<u>Neurology</u>					
RG1450	Alzheimer's disease	Phase III Multinational study	gantenerumab Injection	Roche/MorphoSys	Anti-amyloid-beta human monoclonal antibody
RG7412	Alzheimer's disease	Phase III Multinational study	crenezumab Injection	Roche/AC Immune	Anti-amyloid-beta humanized monoclonal antibody
SA237 / RG6168	Neuromyelitis optica spectrum disorder (NMOSD)	Phase III Multinational study*	satralizumab Injection	In-house (Roche)	Anti-IL-6 receptor recycling antibody

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
RG6206	Duchenne muscular dystrophy (DMD)	Phase II/III Multinational study	Injection	Roche/Bristol-Myers Squibb	Anti-myostatin adnectin
RG7916	Spinal muscular atrophy (SMA)	Phase II/III Multinational study	risdiplam Oral	Roche/PTC Therapeutics	SMN2 splicing modifier
RG7935	Parkinson's disease	Phase I	prasinezumab Injection	Roche/Prothena	Anti- α -synuclein monoclonal antibody
GYM329 / RG6237	Neuromuscular disease	Phase I	Injection	In-house (Roche)	—
RG7906	Psychiatric disorders	Phase I	Oral	Roche	—
Others					
ACE910 / RG6013	Hemophilia A (Non-inhibitor)	Approved (18/10) US	emicizumab Hemlibra Injection	In-house Hemlibra (Roche)	Anti-FIXa/FX bispecific antibody
		Approved (18/12) Japan			
		Filed (18/04) Europe			
RG7716	Diabetic macular edema	Phase III Multinational study	faricimab	Roche	Anti-VEFG/Ang2 bispecific antibody
	Wet age-related macular degeneration	Phase I	Injection		
CIM331**	Pruritus in dialysis patients	Phase II	nemolizumab Injection	In-house	Anti-IL-31 receptor A humanized monoclonal antibody
SKY59 / RG6107	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase I/II Multinational study	Injection	In-house (Roche)	Anti-C5 recycling antibody

Development code	Indication # Additional indication	Stage (Date)	Generic name Product name Dosage form	Origin Overseas name (Collaborator)	Mode of Action
PCO371	Hypoparathyroidism	Phase I	Oral	In-house	PTH1 receptor agonist
AMY109	Endometriosis	Phase I	Injection	In-house	—

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

* Multinational studies managed by Chugai

** Development for atopic dermatitis: Out-licensed to Galderma (Overseas) and Maruho (Japan)

Changes from the last announcement on October 24, 2018

Oncology

- RG7446 Filed → Approved (NSCLC [1st line])
Phase III multinational study → Filed (Small cell lung cancer)
Phase III multinational study → Filed (Breast cancer)
- RG6268 Phase II multinational study → Filed (Solid tumors [*NTRK* fusion-positive])

Neurology

- RG7906 Phase I (Psychiatric disorders : development started)

Others

- ACE910/RG6013 Filed → Approved (Hemophilia A (Non-inhibitor)) [Japan]

R&D Activities

For the changes during FY2018 (January 1 – December 31), please refer to page 4–5 of “CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the fiscal year 2018).”

Changes from January 1 to 31, 2019 are as follows:

Neurology

- We started Phase I study for RG7906 for the expected indication of psychiatric disorders in January 2019.

Major clinical trials in oncology field

Treatment	Expected Indication	Study design	Study name	Stage	Planned filing year
RG3502, Kadcyla	Breast cancer (adjuvant)	Kadcyla + Perjeta vs. Herceptin + Perjeta + chemo	KAITLIN	Phase III	2020
RG7446 (Tecentriq)	Non-small cell lung cancer (NSCLC) [1st line]	PD-L1 positive: Tecentriq vs. chemo	IMpower110	Phase III	-
		TMB* positive: Tecentriq vs. chemo	B-FAST	Phase II/III	
		Non-Squamous: Chemo ± Tecentriq	IMpower132	Phase III	
		Squamous: Chemo ± Tecentriq	IMpower131	Phase III	
	NSCLC (adjuvant)	Tecentriq vs. best supportive care	IMpower010	Phase III	2020
	Small cell lung cancer	carboplatin + etoposide ± Tecentriq	IMpower133	Phase III	Filed
	Urothelial carcinoma (UC)	Tecentriq ± chemo vs. chemo	IMvigor130	Phase III	2021 and beyond
	Muscle invasive UC (adjuvant)	Tecentriq vs. observation	IMvigor010	Phase III	2020
	Renal cell carcinoma	Tecentriq + Avastin vs. sunitinib	IMmotion151	Phase III	2019
	Renal cell carcinoma (adjuvant)	Tecentriq	IMmotion010	Phase III	2021 and beyond
	Breast cancer	TNBC**: nab-paclitaxel ± Tecentriq	IMpassion130	Phase III	Filed
		TNBC: paclitaxel ± Tecentriq	IMpassion131	Phase III	
	Early breast cancer	TNBC (adjuvant): paclitaxel ± Tecentriq	IMpassion030	Phase III	2021 and beyond
		TNBC (neoadjuvant): nab-paclitaxel ± Tecentriq	IMpassion031	Phase III	
	Ovarian cancer	carboplatin + paclitaxel + Avastin ± Tecentriq	IMaGYN050	Phase III	2020
	Prostate cancer	Castration-resistant prostate cancer: enzalutamide ± Tecentriq	IMbassador250	Phase III	2021 and beyond
	Hepatocellular carcinoma	Tecentriq + Avastin vs. sorafenib	IMbrave150	Phase III	2021 and beyond
	Head and neck carcinoma (adjuvant)	Tecentriq	IMvoke010	Phase III	2021 and beyond
RG7440 (ipatasertib)	Prostate cancer	abiraterone ± RG7440	IPATential150	Phase III	2021 and beyond
	Breast cancer	TNBC: paclitaxel ± RG7440 HR+ breast cancer: paclitaxel ± RG7440	IPATunity130	Phase III	2020
RG7596 (polatuzumab vedotin)	DLBCL	Chemo ± RG7596	POLARIX	Phase III	2021 and beyond
RG6264***	Breast cancer	RG6264 (SC) + chemo vs. Herceptin (IV) + Perjeta (IV) + chemo	FeDeriCa	Phase III	2021 and beyond
RG6268 (entrectinib)	Solid tumors	<i>NTRK</i> fusion-positive solid tumors: RG6268	STARTRK2	Phase II	Filed
	NSCLC	<i>ROS1</i> fusion-positive NSCLC: RG6268			2019
AF802, Alecensa	NSCLC (adjuvant)	<i>ALK</i> fusion-positive NSCLC: Alecensa vs. chemo	ALINA	Phase III	2021 and beyond

* TMB: tumor mutational burden

** TNBC: triple negative breast cancer

*** Fixed-dose combination, subcutaneous injection